Galecto, Inc. (NASDAQ:GLTO – Get Free Report) shares traded down 1.9% on Wednesday . The company traded as low as $0.65 and last traded at $0.67. 60,222 shares changed hands during trading, a decline of 75% from the average session volume of 238,462 shares. The stock had previously closed at $0.69.
Galecto Stock Performance
The business’s 50 day moving average price is $0.74 and its two-hundred day moving average price is $0.67.
Galecto (NASDAQ:GLTO – Get Free Report) last issued its earnings results on Friday, March 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.08. On average, sell-side analysts forecast that Galecto, Inc. will post -1.2 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Galecto
Galecto Company Profile
Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Featured Stories
- Five stocks we like better than Galecto
- Technology Stocks Explained: Here’s What to Know About Tech
- Comprehensive Analysis of PayPal Stock
- The How and Why of Investing in Gold Stocks
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- Insider Buying Explained: What Investors Need to Know
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Galecto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galecto and related companies with MarketBeat.com's FREE daily email newsletter.